Abstract
This manuscript describes the Statistical Analysis Plan (SAP) for the following study: Evaluating the Safety and Efficacy of Telemedicine Physician Assessments on a Mobile Stroke Unit: a Prospective Open-Label Blinded End-Point Randomized Controlled Trial (MSU-TELEMED)
This document is a supplement to the MSU-TELEMED study protocol and contains the statistical analysis plan (SAP) for the main paper of the trial in which the primary outcome will be reported. This document complies with the guidelines for the content of statistical analysis plans in clinical trials
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05991310
Funding Statement
This study is supported by a Clinical Investigator Award grant provided by the Sylvia and Charles Viertel Charitable Foundation (ViertelCI23020) and receives support from the Medical Research Future Fund "Golden Hour" Frontiers grant (RHRHPSI000005).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee of the Royal Melbourne Hospital (HREC 2023.110) gave ethics approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.